18 April 2019
Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, announces that it will hold a presentation for investors on Tuesday, 30 April 2019.
The briefing by Dr Paul Kerr, CEO of Fusion, will take place at Copper Bar, Balls Brothers, 6 Adams Court, Old Broad Street, London EC2N 1DX from 4.30pm for a 4.45pm start and will be followed by drinks and networking. If you would like to register to attend, please contact Walbrook PR on 020 7933 8780 or email [email protected].
|Walbrook PR||Tel: +44 (0)20 7933 8780 or[email protected]|
|Paul McManus||Mob: +44 (0)7980 541 893|
|Anna Dunphy||Mob: +44 (0)7876 741 001|
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced over 250 antibodies and successfully completed over 100 humanisation projects for its international, blue-chip client base, which includes eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. It was initially a drug development business but revised its operations to focus on CRO work in 2011. The Company has a highly experienced management team with a combined 47 years' experience in the biopharma industry.
The global monoclonal antibody therapeutics market, which accounted for 43 per cent. of the global biologics market in 2016, was valued at between $85.4 billion and $86.7 billion in 2015 and is forecast to increase at a CAGR of between 8.2 per cent. and 12.2 per cent. for the period 2016 to 2024.